Immunome, Inc.

1.1 History & Prior Art

Immunome acquired varegacestat (formerly AL102) from Ayala Pharmaceuticals in March 2024, assuming a license that Ayala had obtained from Bristol-Myers Squibb in 2017. The asset purchase agreement closed on February 5, 2024 [T1, SEC 10-Q: “We acquired varegacestat from Ayala Pharmaceuticals, Inc., or Ayala, in March 2024.” (C1493); T1, SEC S-3 filing: “we acquired the License Agreement from Ayala pursuant to the Asset Purchase Agreement, dated as of February 5, 2024.” (C2193)].

Immunome owns U.S. patent US12274754B2, “Immunoconjugates and methods,” which claims immunoconjugates that link a ROR1-binding antibody to a topoisomerase I inhibitor payload [T1, Google Patents: “Assignee: Immunome Inc”; claims 2-8 describe ROR1-binding antibodies with specified CDRs and VH/VL sequences (C1879)(C1880)(C1881)(C1882)(C1883)(C1884)(C1885)(C1886)(C1887)(C1888)(C1889)(C1890)(C1891)(C1892)(C1893)(C1894)(C1895)(C1896)(C1897)(C1898)(C1899)(C1900)(C1901)].

Earlier, Immunome built its discovery engine on a proprietary hybridoma technology that immortalizes memory B cells from oncology patient samples. This platform now stands separate from the company’s current ADC and radioligand focus [T1, SEC S-3 filing: “Our discovery platform provides us with a proprietary hybridoma technology to immortalize memory B cells isolated from oncology patient samples.” (C581)].

1.2 Novelty Assessment

Two elements distinguish Immunome’s current pipeline: IM-1021, a ROR1-targeted ADC carrying the proprietary TOPi payload HC74, and IM-3050, a lutetium-177 radioligand therapy that targets fibroblast activation protein (FAP) on cancer-associated fibroblasts across many solid tumors [T1, SEC 10-Q: “IM-1021 is a ROR1 ADC that incorporates HC74, our proprietary TOP1i payload.” (C1494); T1, SEC 10-Q: “FAP is expressed in 75% of solid tumors.” (C1500)]. Beyond these assets, the dossier contains no evidence for other claimed platform novelties—hybridoma count, novel target numbers—leaving those claims unverified.

2.1 Target Biology

Desmoid tumors arise from constitutive Wnt pathway activation driven by CTNNB1 mutations in sporadic cases and APC mutations in familial adenomatous polyposis-associated disease. Wnt dysregulation turns on Notch signaling, which requires γ-secretase to cleave the Notch intracellular domain for nuclear translocation and tumor progression. Varegacestat inhibits γ-secretase, directly blocking this cascade [T2, NPJ Precis Oncol: “Given the role γ-secretase plays in Notch signaling through cleavage of the Notch intracellular domain…”; “Both sporadic DT and familial adenomatous polyposis (FAP)-associated DT are linked to constitutive activation of the Wnt signaling pathway…”; “Cross-talk between the Notch and Wnt pathways… suggest a possible therapeutic target for DT.” (C1011)(C1012)(C1013)(C1014)(C1015)(C1016)(C1017)(C1018)(C1019); T1, CT.gov: “AL102 is an inhibitor of gamma secretase-mediated Notch signaling.” (C060)].

For IM-3050, cancer-associated fibroblasts in roughly 75% of solid tumors express FAP, supporting the broad potential of a FAP-targeted radioligand.

2.2 Validation Layers

The FDA approved nirogacestat (OGSIVEO), another GSI, for progressing desmoid tumors in November 2023, establishing clinical proof of mechanism [T1, FDA label: “OGSIVEO is indicated for adult patients with progressing desmoid tumors who require systemic treatment.” (C3049)(C1080)]. A review article places varegacestat alongside nirogacestat as a later-stage GSI [T2, NPJ Precis Oncol: “Two GSIs, nirogacestat (PF-03084014) and AL102 are in later-stage clinical development.” (C1021)].

Varegacestat’s pivotal Phase 3 RINGSIDE trial met its primary endpoint of progression-free survival, showing an 84% reduction in the risk of disease progression or death versus placebo (HR=0.16, p<0.0001). Key secondary endpoints were strongly positive: objective response rate 56% vs. 9% (p<0.0001), and median best change in tumor volume −83% vs. +11% [T1, SEC 8-K: “with a statistically significant and clinically meaningful 84% reduction…”; “achieving an objective response rate of 56% vs. 9% with placebo (p<0.0001)”; “median best change in tumor volume of −83% vs. +11% with placebo” (C2465)(C2467)(C2468)].

2.3 Target Validation Score

Human genetics (CTNNB1 mutations), a positive randomized Phase 3 readout, and an approved same-class drug validate the target. Formal scoring lacks computational validation metrics, so we omit it.

3.1 Data Summary

Varegacestat (AL102). The Phase 3 RINGSIDE trial (NCT04871282) randomized 198 patients double-blind to varegacestat or placebo. Topline results, announced in December 2025, revealed an 84% reduction in risk of disease progression or death (HR=0.16, p<0.0001), an objective response rate of 56% versus 9% (p<0.0001), and a median tumor volume reduction of 83% versus an 11% increase on placebo. Safety descriptors matched the gamma secretase inhibitor class [T1, SEC 8-K (C2465)(C2466)(C2467)(C2468)(C2469)(C2470); CT.gov primary and secondary endpoints (C128)(C129)(C130)(C131)(C132)(C133)(C134); enrollment (C766)].

IM-1021 (ROR1 ADC). A Phase 1 open-label, dose-escalation/expansion study in advanced B-cell lymphomas and solid tumors (NCT06823167) dosed its first patient in February 2025. Preclinical models demonstrated sustained tumor regression in triple-negative breast cancer and mantle cell lymphoma. Initial clinical data are expected in 2026 [T1, SEC 10-Q (C1495)(C1496); CT.gov (C1617)(C1647); T1, SEC 8-K (C2459)(C2473)(C2474)].

IM-3050 (FAP-targeted RLT). A Phase 1 trial (NCT07505771) plans to enroll 105 participants to assess safety, dosimetry, and preliminary activity, starting in April 2026 with primary completion in December 2029. Preclinical data presented at AACR 2024 showed potent antitumor activity in a xenograft model [T1, CT.gov (C1111)(C1112); T3, PR (C113)(C107)].

3.2 Anti-Anchor Check

Varegacestat delivered positive primary and key secondary endpoints (p<0.0001). The data show no anti-anchor signal.

4.1 Class-Wide Signals

The FDA-approved GSI nirogacestat defines the class safety profile. In the DeFi trial, diarrhea occurred in 84% of patients (Grade 3: 16%) and drove most dose modifications. Ovarian toxicity affected 75% of females of reproductive potential. ALT elevations >5×ULN occurred in 6%, AST in 2.9%. New non-melanoma skin cancers (cutaneous squamous cell carcinoma 2.9%, basal cell carcinoma 1.4%) and hypophosphatemia (65% all grades) also appeared. Animal data revealed embryo-fetal toxicity, triggering pregnancy and contraception warnings [T1, FDA label (C3050)(C3051)(C3052)(C3053)(C3054)(C3055)(C3056)(C3057)(C3058)(C3059)(C3060)(C3061)(C3062)(C3086)(C3151)(C3152)(C3153)(C3154)(C3155)(C3156)(C3157)(C3158)(C3159)].

The dossier contains no FAERS-based disproportionality analysis. The Phase 3 RINGSIDE trial described varegacestat’s safety as “generally well tolerated with a manageable safety profile consistent with the gamma secretase inhibitor class,” but Immunome has not disclosed specific adverse event frequencies for varegacestat [T1, SEC 8-K (C2469)(C2470)].

4.2 Kill Shots

Based on the class label, the most serious safety concerns are ovarian dysfunction (including possible infertility), liver enzyme elevations, and embryo-fetal harm. Ovarian toxicity is a known GSI effect; in DeFi, 75% of women of reproductive potential experienced it.

5.1 Chain of Title

Immunome holds an exclusive worldwide, sublicensable license from BMS—originally granted to Ayala in 2017 and acquired by Immunome in 2024—to develop, manufacture, and commercialize AL102 (varegacestat) and AL101. Immunome now owns the IND for these compounds [T1, SEC S-3 filing: “BMS has granted us a worldwide, non-transferable, exclusive, sublicensable license under certain patent rights …”; “We acquired the License Agreement from Ayala pursuant to the Asset Purchase Agreement, dated as of February 5, 2024.”; “Immunome now owns any IND for the BMS-licensed compounds.” (C2193)(C2194)(C2196)].

For its ADC platform, Immunome owns U.S. patent US12274754B2, which claims immunoconjugates linking a ROR1-targeted antibody to a topoisomerase I inhibitor payload, and has exclusively licensed a novel linker-payload unit from Zentalis Pharmaceuticals [T1, Google Patents claims 2-8 (C1879)(C1880)(C1881)(C1882)(C1883)(C1884)(C1885)(C1886)(C1887)(C1888)(C1889)(C1890)(C1891)(C1892)(C1893)(C1894)(C1895)(C1896)(C1897)(C1898)(C1899)(C1900)(C1901); T1, SEC S-3 filing: “The novel linker-payload unit we exclusively licensed from Zentalis Pharmaceuticals, Inc.” (C576)].

5.2 Maintenance & Lapse Risk

The dossier lacks verified maintenance-fee payment status or terminal disclaimer records. BMS may terminate the license upon Immunome’s insolvency, material breach, failure to meet development obligations, or a challenge to the licensed patents; Immunome may terminate for convenience or safety issues. These provisions create lapse risk if Immunome misses development milestones [T1, SEC filing (C2198)(C2199)]. The evidence contains no freedom-to-operate analysis.

6.1 Verified Credentials

Clay B. Siegall, Ph.D., serves as CEO and Chairman of the Board. Key executives include Jack Higgins, Ph.D., Chief Scientific Officer (appointed at merger); Max Rosett, Chief Financial Officer (confirmed April 2026); Phil Tsai, Ph.D., Chief Technical Officer (appointed June 2024, formerly SVP at Seagen/Pfizer); and Kinney Horn, Chief Business Officer (appointed May 2024). The board includes Jean-Jacques Bienaimé (former CEO of BioMarin), Isaac Barchas (lead independent director), and James Boylan (CEO of Enavate Sciences, unverified) [T1, DEF14A (C273)(C279)(C280)(C281)(C282)(C283)(C284)(C285)(C286)(C291)(C292)(C293)(C294); T3, PR (C108)(C1247); T2, PR (C2946); T1, SEC 8-K (C2457)].

6.2 Publication Record

A 2022 NPJ Precision Oncology article co-authored by Noah Federman (UCLA) describes desmoid tumor molecular pathogenesis and the role of GSIs. The senior author is not an Immunome employee, but certain patents list “Immunome Inc, Exton, PA, USA” as the inventors’ affiliation [T2, NPJ Precis Oncol (C1011)(C1012)(C1013)(C1014)(C1015)(C1016)(C1017)(C1018)(C1019)(C1020)(C1021)(C1022)(C1023)(C1024)(C1025)(C1026)(C1027); T2, mAbs publication (C194)(C195)(C196)(C197)(C198)(C199)(C200)].

6.3 Flags

Background checks reveal no lawsuits or trading violations. The dossier notes that Dr. Siegall’s 2022 departure from Seagen followed allegations that were later settled; those allegations remain unverified and outside our scope.

7.1 Capital Raised vs. Claimed

In January 2025, Immunome completed an underwritten public offering of 19,354,839 shares at $7.75 per share, generating gross proceeds of approximately $150 million and net proceeds, after $9.0 million in underwriting discounts, of approximately $141.0 million. The company maintains an at-the-market sales agreement with TD Securities for up to $200 million, of which $180 million remained available at the time of filing [T1, SEC prospectus supplement (C1828)(C1829)(C1830)(C1831)(C1832)(C1833)(C1855)(C1856)].

The provided documents lack an explicit cash-runway estimate; the prospectus states an intent to use net proceeds together with existing cash for continued development [T1, SEC filing (C1854)]. We found no insider transaction data in the dossier.

8.1 FDA Precedent & Designations

The FDA’s 2023 approval of nirogacestat (OGSIVEO) for progressing desmoid tumors establishes a precedent for the GSI class and validates PFS as a primary endpoint. Varegacestat received FDA Orphan Drug Designation in November 2023 and EMA Orphan Drug Designation in July 2025 [T1, FDA label (C3049)(C1080); T1, SEC 10-Q (C1492)(C1491)].

8.2 Pathway Feasibility

With positive Phase 3 results, Immunome plans to submit an NDA to the FDA in Q2 2026, supported by ongoing manufacturing and pharmacology work. Given the approved class and the demonstrated PFS benefit, acceptance for review appears moderately likely [T1, SEC 8-K (C2472)(C2462)].

11.1 Contradicted Findings

A 2020 SEC filing stated that IMM-BCP-01 and IMM-ONC-01 “have never been tested in human subjects,” contradicting the terminated Phase 1 trial NCT05429021, which enrolled 9 participants to evaluate IMM-BCP-01 in mild-to-moderate COVID-19 [T1, SEC S-1 filing; T1, CT.gov: “Enrollment Count: 9, Type: ACTUAL” (C706)(C1418)]. Separately, a claimed Schedule 13D filing date of October 12, 2023, conflicts with the actual date of October 15, 2023 [T1, SEC filing: “filing_date: 2023-10-15” (C1085)].

11.2 Unsupported Claims

Many descriptive claims central to Immunome’s narrative lack source verification. These include the memory B-cell platform’s scale (processing >150 patient samples, screening >250,000 hybridomas, identifying >50 novel targets); preclinical ADC programs (IM-1617, IM-1340, IM-1335) with IND timelines and payload attributes; assertions that HC74 overcomes multi-drug resistance and outperforms DXd across 89 cell lines; IM-3050’s IND clearance date; and desmoid tumor prevalence statistics. Without primary sources, these claims remain open questions that could affect perceived pipeline depth and competitive position.

11.3 Existential vs. Manageable

The primary existential risk is the unverified preclinical ADC pipeline. If claims about IM-1617, IM-1340, and IM-1335 prove inaccurate, the company’s future beyond varegacestat would depend solely on IM-1021 and IM-3050, both still in early clinical development.

Manageable risks include the well-characterized GSI class safety profile, shared with an approved product; the issued patent US12274754B2 protecting the ROR1 ADC; and orphan drug designations that provide market exclusivity upon approval.

12.1 Platform Beyond Lead

Immunome plans three additional solid-tumor ADC IND submissions in 2026: IM-1617, IM-1340, and IM-1335 in early, mid, and late 2026, respectively, each reportedly incorporating the HC74 payload. The company also references undisclosed ADCs in discovery and lead optimization with INDs targeted for 2027 and beyond. If these preclinical programs are real, they would broaden the pipeline with three additional ADC programs, though external validation is pending [T1, SEC 8-K (C2460)(C2477)(C2478)(C2479)(C2480)(C2481)(C2482)].

12.2 Repurposing Potential

We found no verified repurposing strategy for existing assets.

12.3 Acquirer Logic

The management team’s deep ADC experience—led by the former CEO of Seagen (acquired for $43 billion)—together with composition-of-matter patent protection on the proprietary TOPi payload and a near-term NDA catalyst for varegacestat, position Immunome as a potential acquisition target for large oncology companies seeking to expand ADC portfolios.